Sanofi axed amlitelimab, the $1.1B next-generation eczema drug that was supposed to succeed its $11.6B blockbuster Dupixent. The problem? It wasn't actually better. Now Sanofi's post-Dupixent immunology strategy has a gaping hole and a ticking patent clock.
A $1.1 Billion Bet, Shelved
Imagine spending years grooming your successor, only to realize they're not actually better than you. That's roughly what just happened at Sanofi.
Last week, the French pharma giant pulled the plug on amlitelimab, its next-generation eczema drug and the crown jewel of an acquisition of biotech Kymab worth up to approximately $1.45 billion (including $1.1 billion upfront and $350 million in contingent milestone payments). The drug was supposed to be the heir apparent to Dupixent, Sanofi's blockbuster immunology franchise that pulled in €10.715 billion in 2023 alone. Instead, Sanofi said the drug "would not represent a meaningful improvement over the current standard of care."
Translation: it's not better than what we already sell.
The Drug That Couldn't Outrun Its Own Parent
Amlitelimab works by blocking something called OX40 ligand, a protein involved in immune signaling. That's a completely different approach from Dupixent, which targets two inflammatory proteins called IL-4 and IL-13. In theory, a different mechanism should mean a different (and hopefully better) profile for patients.
In practice? Not so much. Sanofi ran amlitelimab through a full Phase 3 program, including trials called COAST 2 and SHORE, plus a long-term extension study called ESTUARY. The ESTUARY results actually looked decent: patients 12 and older maintained their response without relapsing, and the safety data was consistent with earlier trials.
But "decent" wasn't going to cut it. Amlitelimab failed a co-primary endpoint in the COAST 2 trial, which is a polite way of saying it didn't pass one of the two main tests it was designed to pass. And across the entire program, the efficacy never clearly separated from Dupixent. When your whole reason for existing is to be better than the market leader, and that market leader is your own company's drug, "roughly equivalent" is a death sentence.
The New CEO Isn't Sentimental
This decision didn't happen in a vacuum. Sanofi is conducting what the company calls an "ongoing strategic assessment" of its pipeline. Translation: leadership is going through the medicine cabinet and tossing anything that doesn't earn its shelf space.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Analysts are reading this as a signal of tighter R&D discipline, not panic. Sanofi didn't change its full-year 2026 financial guidance after the announcement. Wall Street had apparently already started marking down amlitelimab's commercial potential after those mixed Phase 3 results.
One analyst note from AlphaValue put it bluntly: leadership "does not appear willing to invest at a loss in assets with no meaningful chance of prevailing." That's the kind of sentence that sounds like a compliment but stings if you're on the amlitelimab team.
The Dupixent Problem Nobody Wants to Talk About
So where does this leave Sanofi's immunology strategy? In a word: exposed.
Dupixent is an absolute juggernaut. It's approved in over 60 countries across seven to nine indications depending on the market, from eczema to asthma to chronic sinus disease. Sanofi is still expanding its label aggressively, with regulatory decisions pending for allergic fungal rhinosinusitis, bullous pemphigoid, and several pediatric uses. A Phase 3 readout for lichen simplex chronicus is expected in the second half of 2026.
The good news: Dupixent's core U.S. patent protection runs through March 2031 thanks to a patent-term extension, with additional method and formulation patents stretching to 2032-2034. Meaningful biosimilar competition probably won't arrive until the early-to-mid 2030s. Korean biosimilar developers are already circling (one report estimated that capturing just 5% of Dupixent's global sales could generate about $750 million), but they're racing toward a finish line that's still years away.
The bad news: when that cliff eventually comes, Sanofi just lost its most advanced replacement. Amlitelimab was the only named, late-stage next-generation eczema candidate in the company's pipeline. Without it, Sanofi's post-Dupixent playbook in atopic dermatitis looks uncomfortably thin.
The Backup Plan (Such As It Is)
Sanofi isn't completely empty-handed. The company has two early-stage oral drug candidates in eczema: an IRAK4 degrader (partnered with Kymera) and a STAT6 degrader (from Nurix). Both target intracellular signaling pathways and could offer something amlitelimab couldn't, namely the convenience of a pill instead of an injection. But "early-stage" and "could" are doing a lot of heavy lifting in that sentence.
Beyond eczema, Sanofi's broader immunology bench includes frexalimab for lupus and SAR443765 targeting a protein called TSLP for respiratory and allergic conditions. Analyst estimates peg the combined peak sales for these late-stage immunology assets (which until last week included amlitelimab) at €5.2-6.8 billion by 2032. That number just got smaller.
Meanwhile, amlitelimab itself isn't entirely dead. Sanofi is keeping the lights on for a Phase 2 study in celiac disease, where competition is thinner and unmet need is enormous. It's a clever pivot if the data cooperates, but celiac was always the side quest, not the main storyline.
A Warning Shot for the Whole OX40 Class
Sanofi's retreat carries implications well beyond its own pipeline. Amlitelimab's stumble in eczema follows similar struggles for rocatinlimab, another OX40-targeting antibody that hit turbulence in development. Two high-profile setbacks in the same drug class, in the same disease, send a clear message: the bar for beating Dupixent in eczema is brutally high.
The atopic dermatitis market in 2026 is packed. JAK inhibitors like upadacitinib and abrocitinib offer rapid itch relief but carry boxed safety warnings. IL-13 biologics like tralokinumab and lebrikizumab compete on dosing convenience. IL-31-targeting drugs aim to dominate the pruritus (severe itch) niche. And towering over all of them sits Dupixent, the incumbent with a decade of real-world evidence and a label that keeps getting wider.
Breaking into that market requires more than a novel mechanism. It requires clearly superior outcomes, a cleaner safety profile, or a dramatically more convenient format. Amlitelimab offered none of those advantages convincingly enough.
The Bottom Line
Sanofi made the rational call. Pouring another billion into a drug that's roughly as good as your own bestseller, in a market that's already overflowing with options, is a textbook case of throwing good money after bad. The discipline is admirable.
But discipline doesn't fill the strategic hole. Dupixent's patent fortress holds until 2031, giving Sanofi time to find or build its next immunology franchise. The question is whether oral degraders, celiac disease pivots, and bolt-on acquisitions can collectively replace the revenue engine that amlitelimab was supposed to become.
Five years sounds like a lot. In drug development, it's barely enough time to blink.
5 min read
The Only Drug That Can Save These Babies Is Being Pulled Off Shelves
Pfizer just recalled lots of the only drug recommended to treat syphilis in pregnant women, compounding a shortage that's already lasted years. With congenital syphilis cases at historic highs, public health officials are calling it a preventable tragedy in slow motion.
